Haleos Labs: Consolidated Growth Masks Standalone Dip; Subsidiary Loan Guarantee Approved

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAkshat Lakshkar|Published at:
Haleos Labs: Consolidated Growth Masks Standalone Dip; Subsidiary Loan Guarantee Approved
Overview

Haleos Labs (formerly SMS Lifesciences) reported a mixed Q3 FY26. Consolidated revenue climbed 12.0% YoY to ₹94.78 Cr with net profit surging 37.0% YoY to ₹6.65 Cr. However, standalone revenue fell 2.6% and net profit dropped 13.2% YoY. The board approved a ₹20 Cr corporate guarantee for subsidiary Mahi Drugs' borrowing.

📉 The Financial Deep Dive

The Numbers:
Haleos Labs Limited, formerly SMS Lifesciences India Limited, presented a mixed financial performance for the quarter and nine months ended December 31, 2025 (Q3 FY26 and 9M FY26).

  • Consolidated Performance:

    • Q3 FY26 Revenue: ₹9,478.31 Lakhs (approx. ₹94.78 Cr), a 12.0% increase year-on-year (YoY).
    • Q3 FY26 Net Profit: ₹664.89 Lakhs (approx. ₹6.65 Cr), a significant 37.0% surge YoY.
    • Q3 FY26 EPS: ₹21.89, up 21.0% YoY.
    • 9M FY26 Revenue: ₹25,865.54 Lakhs (approx. ₹258.66 Cr), a marginal 1.2% increase YoY.
    • 9M FY26 Net Profit: ₹1,745.63 Lakhs (approx. ₹17.46 Cr), a 14.5% rise YoY.

  • Standalone Performance:

    • Q3 FY26 Revenue: ₹8,071.91 Lakhs (approx. ₹80.72 Cr), down 2.6% YoY.
    • Q3 FY26 Net Profit: ₹540.68 Lakhs (approx. ₹5.41 Cr), a 13.2% decrease YoY.
    • Q3 FY26 EPS: ₹17.88, down 13.2% YoY.
    • 9M FY26 Revenue: ₹23,760.54 Lakhs (approx. ₹237.61 Cr), down 4.2% YoY.
    • 9M FY26 Net Profit: ₹1,554.21 Lakhs (approx. ₹15.54 Cr), down 16.9% YoY.

The Quality:
The stark divergence between consolidated and standalone performance is the most critical takeaway. While the group's overall profitability saw robust growth driven by subsidiary operations, the parent entity (standalone) experienced a decline in both revenue and net profit. This suggests potential operational challenges or different market dynamics affecting the core business, which warrants deeper investigation.

The Grill:
The key question for investors and analysts will be the reason behind the standalone financial contraction despite consolidated growth. Management commentary is crucial to understand the sustainability of the consolidated figures and the strategy to revive the standalone performance. The company operates in a single reportable segment: APIs and intermediates.

🚩 Risks & Outlook

Specific Risks:
A significant risk identified is the approval of a Corporate Guarantee of ₹20 Crores for its subsidiary, Mahi Drugs Private Limited, for an External Commercial Borrowing (ECB). This guarantee introduces a contingent liability for Haleos Labs. Should Mahi Drugs default on its borrowing, Haleos Labs would be obligated to meet the debt, impacting its financial stability and potentially increasing its debt burden.

The Forward View:
Investors should closely monitor the repayment of the ECB by Mahi Drugs and Haleos Labs' strategy to address the declining standalone performance. The company's compliance with new Labour Codes is stated as satisfactory, but ongoing developments will need to be watched. The independent directors' satisfactory review of board performance is a positive governance note.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.